SQZ Biotechnologies attracts $72 mln Series C

Massachusetts-based SQZ Biotechnologies, a cell therapy company, has raised $72 million in Series C financing. The investors included Everblue, Illumina Ventures, Invus, Orient Life, Viva Ventures Biotech Group, Bridger Healthcare Partners, Global Health Science Fund, GV, JDRF T1D Fund, NanoDimension and Polaris.

Source: Press Release

PE Hub Healthcare Wire delivers private equity and M&A healthcare deal activity, fundraising news, people moves, regulatory updates and much more every Thursday. Subscribe now! It’s FREE.

Find new deal opportunities, super-charge your fundraising efforts and track top managers with VCJ. Get your FREE trial! Or subscribe now!